October Surprise: How Amgen’s Aflibercept Launch Shook Up US Biosimilars In 2024

As US Market Approaches Tenth Anniversary Of First Biosimilars Approval And Launch

 
• By Dave Wallace
  
Amgen’s ophthalmic launch surprised the market in 2024 (Shutterstock)

More from Biosimilars

More from Generics Bulletin Perspectives